Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

ANVS

(ANVS)

NYQ – Real vaqt narxi. Valyuta: USD

2.03

-0.12 (-5.58%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

2.05

+0.02 (0.99%)

Bozordan keyin: Mar 27, 2026, 7:56 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

NeuroRPM's AI-enabled Apple Watch-based platform will provide continuous digital biomarker monitoring in Annovis Bio's Parkinson's disease clinical trial.

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a partnership with NeuroRPM , a digital health technology company, to implement a new FDA-cleared artificial intelligence (AI) platform that collects movement data for symptom and disease management in its ongoing Parkinson's study.

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced business updates and reported financial results for the fiscal year 2025.

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 20th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2026), taking place March 17-21, 2026, in Copenhagen, Denmark.

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease

MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that an independent Data and Safety Monitoring Board (DSMB) has issued a positive recommendation regarding the safety of buntanetap at 6 months, supporting the continuation of the ongoing pivotal Phase 3 AD clinical trial without modification.

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will begin an Open-Label Extension (OLE) study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in PD patients.

Annovis to Host Corporate Update Webinar on January 28, 2026

Annovis to Host Corporate Update Webinar on January 28, 2026

MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.

Videolar

No Data

There is no data to display

Press-relizlar

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

NeuroRPM's AI-enabled Apple Watch-based platform will provide continuous digital biomarker monitoring in Annovis Bio's Parkinson's disease clinical trial.

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a partnership with NeuroRPM , a digital health technology company, to implement a new FDA-cleared artificial intelligence (AI) platform that collects movement data for symptom and disease management in its ongoing Parkinson's study.

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced business updates and reported financial results for the fiscal year 2025.

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 20th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2026), taking place March 17-21, 2026, in Copenhagen, Denmark.